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Abstract
Background: This study investigated potential prognostic factors in patients treated with whole-brain irradiation
(WBI) alone for brain metastases from relatively radioresistant tumors such as malignant melanoma, renal cell
carcinoma, and colorectal cancer. Additionally, a potential benefit from escalating the radiation dose was
investigated.
Methods: Data from 220 patients were retrospectively analyzed for overall survival and local control. Nine potential
prognostic factors were evaluated: tumor type, WBI schedule, age, gender, Karnofsky performance score, number of
brain metastases, extracerebral metastases, interval from diagnosis of cancer to WBI, and recursive partitioning
analysis (RPA) class.
Results: Survival rates at 6 and 12 months were 32% and 19%, respectively. In the multivariate analysis, WBI doses
>30 Gy (p = 0.038), KPS ≥70 (p < 0.001), only 1-3 brain metastases (p = 0.007), no extracerebral metastases (p <
0.001), and RPA class 1 (p < 0.001) were associated with improved survival. Local control rates at 6 and 12 months
were 37% and 15%, respectively. In the multivariate analyses, KPS ≥70 (p < 0.001), only 1-3 brain metastases (p <
0.001), and RPA class 1 (p < 0.001) were associated with improved local control. In RPA class 3 patients, survival
rates at 6 months were 10% (35 of 39 patients) after 10 × 3 Gy and 9% (2 of 23 patients) after greater doses,
respectively (p = 0.98).
Conclusions: Improved outcomes were associated with WBI doses >30 Gy, better performance status, fewer brain
metastases, lack of extracerebral metastases, and lower RPA class. Patients receiving WBI alone appear to benefit
from WBI doses >30 Gy. However, such a benefit is limited to RPA class 1 or 2 patients.
Background
Malignant melanoma, renal cell carcinoma, and colorec-
tal cancer are considered relatively radioresistant
tumors. Little data exist regarding the radiotherapy of
brain metastases from such tumors. Brain metastases
develop in up to 46% of melanoma patients, 4-11% of
renal cell carcinoma patients, and in 0.3-9% of colorec-
tal cancer patients [1-6]. The median survival time of
t h e s ep a t i e n t si so n l yaf e wm o n t h s[ 7 - 9 ] .W h o l e - b r a i n
irradiation (WBI) alone still is the most commonly
administered treatment. The most frequently applied
radiation schedule is 10 × 3 Gy in two weeks. In care-
fully selected patients, more aggressive treatment
options including neurosurgery or radiosurgery may be
justified to extend survival. However, these more aggres-
sive treatments may be associated with increased risk.
Thus, it is important to individualize the treatment
approach for each patient taking into account his or
her prognosis.
The major objective of the present study was the defi-
nition of significant prognostic factors for overall survi-
val and local control following WBI for brain metastases
from a relatively radioresistant tumor. Such prognostic
factors can help the physician select the appropriate
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nostic factors are important for proper stratification in
future trials. Additionally, this study investigated the
potential benefit from an escalation of the WBI dose
beyond 10 × 3 Gy with respect to overall survival and
local control.
Methods
A total of 220 patients who were treated with WBI
alone for brain metastases from a relatively radioresis-
tant tumor such as malignant melanoma (N = 69), renal
cell carcinoma (N = 74) or colorectal cancer (N = 77)
between 1989 and 2008 were included in this retrospec-
tive analysis. Further criteria for inclusion were as fol-
lows: no prior radiotherapy to the brain, confirmation
by computed tomography or magnetic resonance ima-
ging, and administration of dexamethasone (12-32 mg/
day) during WBI. The data were obtained from the
patients, their general practitioners, treating oncologists,
and patient files. The data have been analysed anon-
ymously. The study has been approved by the ethic
committee of the University of Lubeck. Patient charac-
teristics are summarized in Table 1. The patients treated
in Tilburg received 5 × 4 Gy in one week and those
patients treated at the University of Lubeck received 10
× 3 Gy. At the University of Hamburg the radiation
schedule varied based on the discretion of the treating
physician. Most patients treated in Hamburg received
doses beyond 30 Gy, i.e. 15 × 3 Gy in three weeks or 20
× 2 Gy in four weeks.
WBI was perfomed with 6-10 MV photon beams from
a linear accelerator via parallel opposed fields (90° and
270°).
The following potential prognostic factors were evalu-
ated: primary tumor type (malignant melanoma versus
renal cell carcinoma versus and colorectal cancer),
radiation schedule (5 × 4 Gy in one week versus 10 × 3
Gy in two weeks versus 15 × 3 Gy in three weeks or 20
× 2 Gy in four weeks), age (≤62 versus ≥63 years, med-
ian age: 63 years), gender, Karnofsky performance score
(KPS <70 versus KPS ≥70), number of brain metastases
(1-3 versus ≥4), presence of extracerebral metastases at
the time of WBI (no versus yes), interval between first
diagnosis of cancer and WBI (≤24 versus ≥25 months),
and RPA (RPA 1 versus RPA 2 versus RPA 3).
Gaspar et al. identified three RPA classes based on
data from Radiation Therapy Oncology Group (RTOG)
brain metastases trials [10]. RPA class 1 patients have a
Karnofsky Performance Score (KPS) ≥70, age <65 years,
no extracerebral metastases, and a controlled primary
tumor. RPA class 2 patients have a KPS ≥70, and at
least one unfavorable prognostic factor such as age ≥65
years, extracerebral metastases, or uncontrolled primary
tumor. RPA class 3 includes all patients with a KPS <70.
The median survival for the RPA classes 1, 2, and 3
were 7.1 months, 4.2 months, and 2.3 months, respec-
tively [10].
Local control was defined as the absence of progres-
sive or recurrent brain metastasis. The diagnosis of pro-
gression or recurrence was confirmed by computed
tomography (CT) or magnetic resonance imaging (MRI).
All patients had CT or MRI scans obtained if neurologic
deterioration or other symptoms most likely related to
progression of brain metastases occurred. Local recur-
rence was defined progression of treated lesions or pro-
gression elsewhere in the brain. Time to death and to
local recurrence was measured from the completion of
radiotherapy.
Overall survival and local control rates were calculated
using the Kaplan-Meier-method [11]. Differences
between the Kaplan-Meier curves were determined with
the log-rank test (univariate analysis). The prognostic fac-
t o r sf o u n dt ob es i g n i f i c a n t( p<0 . 0 5 )i nt h eu n i v a r i a t e
Table 1 Patient characteristics
N( % )
Tumor type
Malignant melanoma 69
Renal cell carcinoma 74
Colorectal cancer 77
WBI schedule
5×4G y 5 6
10 × 3 Gy 99
15 × 3/20 × 2 Gy 65
Age
≤ 62 years 109
≥ 63 years 111
Gender
Female 78
Male 142
Karnofsky Performance Score
<70 89
≥ 70 131
Number of metastases
1-3 89
≥4 131
Extracerebral metastases
No 68
Yes 152
Interval from first diagnosis to WBI
≤ 24 months 104
≥ 25 months 116
RPA class
12 5
2 105
39 0
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was performed with the Cox proportional hazards model.
The patients were followed until death or for median 8.5
months (range: 6-54 months) in those who were alive at
last follow up. If both RPA class and any factor contribut-
ing to the RPA class (age, KPS, extracerebral metastases)
were significant in the univariate analysis, two multivari-
ate analyses were performed. One multivariate analysis
included the RPA class but none of the three other con-
founding factors and the seco n da n a l y s i si n c l u d e dt h e
three other factors but not RPA.
Results
Median survival time for the entire cohort was 3.5
months. The survival rates at 6 months and 12 months
were 32% and 19%, respectively. In the univariate analy-
sis, better overall survival was associated with the WBI
s c h e d u l e( 1 5×3G y / 2 0×2G y ,p<0 . 0 0 1 ) ,K P S≥70
(p < 0.001), only 1-3 brain metastases (p < 0.001),
absence of extracerebral metastases at the time of WBI
(p < 0.001), and RPA class 1 (p < 0.001). The results of
t h eu n i v a r i a t ea n a l y s i sf o ro v e r a l ls u r v i v a la r es u m m a r -
ized in Table 2. In the multivariate analysis of overall
survival, WBI schedule (hazard risk [HR]: 1.23; 95%-
confidence interval [CI]: 1.01-1.49; p = 0.038), KPS (HR:
2.06; 95%-CI: 1.49-2.86; p < 0.001), number of brain
metastases (HR: 1.18; 95%-CI: 1.05-1.34; p = 0.007),
extracerebral metastases (HR: 1.57; 95%-CI: 1.10-2.28;
p = 0.012), and RPA class (HR: 2.15; 95%-CI: 1.65-2.82;
p < 0.001) maintained significance.
In the subgroup of the RPA class 3 patients, the survi-
val rates at 6 months were 10% (35 of 39 patients) after
10 × 3 Gy and 9% (2 of 23 patients) after 15 × 3 Gy/20 ×
2 Gy, respectively (p = 0.98).
The median time to recurrence for the entire cohort
was 4.5 months. The local control rates at 6 months
and 12 months were 37% and 15%, respectively. In the
univariate analysis, better local control was associated
with the WBI schedule (15 × 3 Gy/20 × 2 Gy, p <
0.001), KPS ≥70 (p < 0.001), only 1-3 brain metastases
(p < 0.001), and RPA class 1 (p < 0.001). The results of
the univariate analysis for local control are summarized
in Table 3. In the multivariate analysis of local control,
KPS (HR: 1.97; 95%-CI: 1.35-2.86; p < 0.001), number of
brain metastases (HR: 1.36; 95%-CI: 1.18-1.57; p <
0.001), and RPA class (HR: 1.88; 95%-CI: 1.41-2.53; p <
0.001) maintained significance, whereas the WBI sche-
dule was not significant (HR: 1.08; 95%-CI: 0.87-1.34;
p = 0.46).
Acute toxicity grade ≥2 according to the Common
Toxicity Criteria 2.0 [12] occurred in 17/99 (17%)
patients who received 30 Gy in 10 fractions, and 12/65
(18%) patients who received greater doses. Neurocogni-
tive deficits most likely related to WBI were observed in
6/99 (6%) patients who received 30 Gy in 10 fractions
and 5/65 (8%) patients who received greater doses.
Discussion
Only limited data exist regarding the treatment of brain
metastaes from relatively radioresistant tumors such
malignant melanoma, renal cell carcinoma, and colorec-
tal cancer. Farnell et al. presented a retrospective series
of 146 patients with brain metastases from colorectal
cancer [13]. Thirty-nine patients received surgery plus
WBI, 11 patients surgery alone, 79 patients WBI alone,
and 17 patients supportive care alone. The median sur-
vival times were 42, 45, 16 and 8 weeks, respectively.
Ikushima et al. reported median overall survival times of
26 months after fractionated stereotactic radiotherapy,
of 19 months after surgery followed by WBRT, and of
4 months after WBRT alone in a retrospective series of
Table 2 Univariate analysis of survival
At 6
months
At 12
months
(%) (%) P
Tumor type
Malignant melanoma 32 8
Renal cell carcinoma 38 30
Colorectal cancer 26 18 0.08
WBI schedule
5×4G y 2 3 8
10 × 3 Gy 24 14
15 × 3/20 × 2 Gy 51 37 <0.001
Age
≤62 years 38 22
≥63 years 26 17 0.10
Gender
Female 26 24
Male 35 18 0.52
Karnofsky Performance Score
<70 7 2
≥70 49 32 <0.001
Number of metastases
1-3 54 38
≥41 7 6 <0.001
Extracerebral metastases
No 57 32
Yes 20 13 <0.001
Interval from first diagnosis to
WBI
≤24 months 31 16
≥25 months 33 21 0.30
RPA class
19 6 6 1
23 7 2 5
38 2 <0.001
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noma and a comparably good performance status [14].
Prognostic factors may aid the clinician select the
most appropriate treatment regimen for the individual
patient. Several scoring systems exist that allow one to
estimate the survival prognosis of patients with brain
metastases [10,15]. Brain metastases from different
tumor entities vary with respect to their radiobiological
behavior. Some entities such as malignant melanoma,
renal cell carcinoma and colorectal cancer are consid-
ered relatively radioresistant. None of the previously
reported scoring systems focused on these particular
tumors.
The present study identified prognostic factors asso-
ciated with survival and local control for patients who
received WBI alone for brain metastases from these
radioresistant tumor types. On multivariate analyses,
overall survival was significantly associated with WBI
schedule, KPS, number of brain metastases, extracereb-
ral metastases at the time of WBI, and RPA class. Local
control was significantly associated with KPS, number of
brain metastases, and RPA class. Regarding the WBI
schedule, doses higher than 10 × 3 Gy resulted in better
overall survival than standard doses of 10 × 3 Gy and 5
× 4 Gy. Better local control after doses higher than 10 ×
3 Gy was observed only in the univariate analysis. In a
recently published meta-aanalysis, altered dose-fractio-
nation schedules of WBI did not result in significant dif-
ferences in median survival and local control [16], which
is different from the findings of the present study. This
difference can be explained by the fact that the data
from the meta-analysis were mostly derived from differ-
ent, less radioresistant tumor entities. However, the ret-
rospective design of the present study should be
considered when interpreting these results. Retrospective
studies are always at risk of including hidden biases.
The biological effectiveness of irradiation depends on
both the total dose and the dose per fraction. Different
radiation schedules can be compared with the Equivalent
Dose in 2 Gray Fractions (EQD2), calculated with the
equation EQD2 = D [(d + a/b)/(2 Gy + a/b)], as derived
from the linear-quadratic model; D = total dose, d = dose
per fraction, a = linear (first-order dose-dependent) com-
ponent of cell killing, b = quadratic (second-order dose
dependent) component of cell killing, a/b-ratio = the
dose at which both components of cell killing are equal
[17]. Assuming a a/b-ratio of 3 Gy for tumor cell kill in
relatively radioresistant tumors, the EQD2 of the radia-
tion schedules are 28 Gy3 (5 × 4 Gy), 36 Gy3 (10 × 3 Gy),
40 Gy3 (20 × 2 Gy), and 54 Gy3 (15 × 3 Gy), respectively.
In the present study, fractionation schedules with a
higher EQD2 resulted in better overall survival. However,
such a benefit was limited to RPA class 1 or RPA class 2
patients, and did not apply to RPA class 3 patients.
Furthermore, our data suggest that the RPA classifica-
tion which was based primarily on studies including a
large variety of different primary tumors, mostly breast
cancer and lung cancer patients, applies well to rela-
tively radioresistant tumors. KPS and extracerebral con-
trol are the most important prognostic factors of the
RPA classification [10]. The number of brain metastases
has been identified as a significant predictor for overall
survival in a retrospective series of 1,797 patients,
mostly lung cancer and breast cancer patients, treated
with different treatment regimens including WBI alone
[15]. In that large retrospective analysis, local control
was associated with performance status and extracereb-
ral metastases as in the present study. The RPA class
has not been investigated in that large retrospective ser-
ies. However, the RPA class is closely related to the
KPS. A potential benefit from WBI doses higher than
Table 3 Univariate analysis of local control
At 6
months
At 12
months
(%) (%) P
Tumor type
Malignant melanoma 37 5
Renal cell carcinoma 41 22
Colorectal cancer 33 14 0.36
WBI schedule
5×4G y 4 2 0
10 × 3 Gy 20 4
15 × 3/20 × 2 Gy 53 30 <0.001
Age
≤ 62 years 42 13
≥ 63 years 31 18 0.63
Gender
Female 33 16
Male 39 14 0.32
Karnofsky Performance Score
<7 0 1 2 0
≥ 70 50 23 <0.001
Number of metastases
1-3 60 28
≥41 8 0 <0.001
Extracerebral metastases
No 45 21
Yes 32 10 0.10
Interval from first diagnosis to
WBI
≤ 24 months 37 10
≥ 25 months 37 19 0.44
RPA class
18 0 3 8
24 2 1 8
31 2 0 <0.001
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of melanoma patients. Isokangas et al. observed a signifi-
cantly better median survival time with radiation doses
higher than 30 Gy when compared to doses of 30 Gy or
less (9.6 versus 4.1 months, p < 0.001) [18]. However, in
comparison to our present study, the fractionation sche-
dules of the study by Isokangas et al. were more inhomo-
geneous with total doses ranging from 9 Gy to 60 Gy and
doses per fraction ranging from 2 to 4 Gy. A retrospective
study of 46 patients with brain metastases from RCC has
been reported by Cannady et al. [8]. Median survival times
were 2.7 months for 10 × 3 Gy, 0.4 months for doses <30
Gy and 8.5 months for doses >30 Gy, respectively (P =
0.029). The median overall survival times of the latter
two studies and of the present study are summarized in
Table 4.
Conclusions
Improved overall survival was associated with WBI
doses higher than 10 × 3 Gy, better performance status,
fewer brain metastases, lack of extracerebral metastases,
and lower RPA class. Improved local control was asso-
ciated with better performance status, fewer brain
metastases, and lower RPA class. Patients with a rela-
tively favorable prognosis may receive neurosurgery or
radiosurgery in addition to WBI as these treatments
have been shown to improve survival in select patients.
Patients who are treated with WBI alone appear to ben-
efit from an escalation of the WBI dose beyond 10 × 3
Gy. However, such a benefit was limited to RPA class 1
or RPA class 2 patients Further dose-fractionation stu-
dies are required to confirm the latter results.
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